XOMA reformulates its topical acne treatment

By Lisa Kerner

Charlotte, N.C., Sept. 7 - XOMA Ltd. said its reformulated XOMA 629 (formerly XMP.629) meets the company's requirements for skin penetration and anti-microbial activity in the treatment of mild to moderate acne.

Preclinical trials of the reformulated topically applied drug are underway, with phase one clinical trials planned for 2007.

The Berkeley, Calif.-based pharmaceutical company said it expects to also amend its Investigational New Drug application.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.